The latest enterprise AI gains are often real, but the biggest returns still go to organizations willing to rewrite workflows, incentives, and decision rights instead of just adding a chatbot to old habits.
Novo Nordisk’s use of process mining shows why AI value in regulated drug development is often harder to prove than to promise.
In complex drug development, AI can make individual tasks faster, but the harder problem is proving whether that speed becomes real enterprise value.
The strongest AI programs do not just automate tasks - they force organizations to confront broken approvals, unclear ownership, and the process debt that turns speed into friction.
Global Business Support Centers are shifting from support functions to managed decision environments, where AI, process mining, document processing, and agentic automation can reshape how work is supervised, measured, and adapted.
The sharper lesson in modern automation is not how much work can be handed to software, but how well teams can see real process behavior before granting autonomy.
As autonomous automation spreads, the real decision is no longer which dashboard looks best, but which platform can model business reality well enough to support AI and process change.
Healthcare keeps producing more data, but the harder problem is turning that noise into a workflow view clinicians can trust, review, and act on.
Process mining is quietly transforming business operations, revealing inefficiencies and risks that managers never knew existed.